Cardiac MRI After Pacemaker Replacement

Magnetic Resonance Imaging Clinical Trial

— MRI-rePACE  

Official title:

Cardiac MRI After Replacement of Long Term Implanted PACEmakers by a MRI Conditional Pulse Generator (MRI-rePace)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02195024
• Other study ID #: PMUN-DB-001-MRIPM
• Status: Terminated
• Phase: Phase 4
• Start date: July 2014
• Est. completion date: May 2017

Study information

• Verified date: January 2021
• Source: Paracelsus Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aim of this trial is to investigate feasibility of cardiac magnetic resonance imaging (cMRI) in patients with long term implanted coradial leads upgraded to an MRI conditional pacemaker system, to assess MR-image quality and to prove the safety of MRI in this specific population in the short term as well as during long term follow-up.

Description:

The trial is designed

1. To investigate the cardiac MRI related adverse event-free rate in patients with long term implanted coradial pacing leads (Fineline-II) after implantable pulse generator (IPG) exchange to a MRI conditional system (short term and long term): Safety.

2. To assess the technical performance of MRI conditional pacemaker systems with long term implanted coradial pacing leads, for cardiac MRI (short term and long term): Effectiveness pacemaker.

3. To assess the image quality (IQ) and the diagnostic value (DV) of the cardiac MRI scans in patients with implanted MRI conditional systems: Effectiveness cardiac MRI.

2) To evaluate the clinical incidence of MRI procedures in the population of long term implanted pacemaker patients (long term-follow up)

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 23
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Approved clinical indication for pectoral pacemaker exchange (e.g. elective replacement indication (ERI), end of service (EOS))

• Implantation of a CE certified / market released MRI conditional pacemaker (BSCI) consistent of

• a single or dual chamber MRI conditional pacemaker (BSCI) or

• Any comparable successor IPG (MRI conditional system, BSCI) compatible with

• Implanted Fineline-II-leads (BSCI), MRI conditional

• Leads electrically intact and with stable and normal function

• The ascertained lead impedance is between 200 and 1500 Ohm.

• All pacing capture thresholds (PCT) do not exceed 2.0 V @0.4 or 0.5 ms in pacemaker dependent patients

• Adherence to the MRI conditions of use is given

• Male or female 18 years or older

• Understand the nature of the procedure

• Give written informed consent

• Able to complete all testing required by the clinical protocol

• Ability to measure atrial and/or ventricular pacing threshold(s) at 0.4 or 0.5 ms

• Patient body height greater or equal to 140 cm

• Pectoral implanted device

• Subjects who are able and willing to undergo elective cardiac magnetic resonance (MR) scanning without sedation (MRI-group)

• Subjects who are geographically stable and available for follow-up at the study center for the length of the study

Exclusion Criteria:

• • Non MRI conditional leads implanted

• Pacing threshold(s) (at 0.4 or 0.5 ms) and/or sensing amplitude(s) and/or impedance(s) are not measurable

• Meet one or more of the contraindications for MRI including Psychiatric disorders, anxiety, claustrophobia Cardiac disorders that represent a contraindication to MRI

• Cardiac surgery already scheduled in the next three months

• Have other medical implants that may interact with MRI, e.g. abandoned implantable cardioverter defibrillator (ICD) leads or pacemaker leads other than MRI conditional, lead extensions, other active medical devices, non-MRI compatible devices, mechanical valve

• Have other metallic artifacts/components in body that may interact with MRI

• Subjects for whom a single dose of 1.0 milligram (mg) dexamethasone acetate may be contraindicated

• Subjects who require a legally authorized representative to obtain consent

• Subjects who are immediate candidates for an ICD

• Subjects with medical conditions that preclude the testing required by the protocol or limit study participation

• Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during this clinical study

• Being pregnant

• Have a life expectancy of less than three months

• Subjects with exclusion criteria required by local law (e.g. age, breastfeeding)

Related Conditions & MeSH terms

• Bradycardia
• Cardiac Pacemaker
• Magnetic Resonance Imaging

Intervention

Procedure:
• cardiac MRI group
• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans = six (6) weeks after device exchange

Locations

Country	Name	City	State
Germany	Klinikum Nürnberg Süd	Nürnberg

Sponsors (2)

Lead Sponsor	Collaborator
Dr. Dirk Bastian	Boston Scientific Corporation

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	cMRI periprocedural observations / complaints	Periprocedural observations / complaints during MRI; - Time interval: during MRI scanning, between pre- and post-MRI pacemaker interrogation	during cardiac MRI between pre- and post-MRI pacemaker interrogation
Other	IPG dysfunction	- Any IPG dysfunction (reset, reprogramming, over/undersensing, over-/underpacing, exit-block, loss of capture…), Battery changes	after cMRI at any follow-up until the end of the trial (minimum 24 months)
Primary	safety: cardiac MRI and pacing system related Serious Adverse Device Effects	Primary outcome measure 1 (safety): cMRI and pacing system related Serious Adverse Device Effect (SADE) free rate after 3 months.; Hypothesis: MRI and pacing system related Serious Adverse Device Effect (SADE) free-Rate is greater than 90% after 3 months.	3 months after cardiac MRI
Primary	Effectiveness cardiac MRI: cMRI image quality (IQ) and diagnostic value (DV)	Primary outcome measure 2 (Effectiveness cardiac MRI): cMRI image quality (IQ) and diagnostic value (DV); Hypothesis: cMRI IQ is "acceptable" and clinical use is not adversely affected in = 90% cMRI procedures	cMRI images done = six (6) weeks after device exchange
Secondary	cMRI and pacing system related Adverse Device Effect	The proportion of patients with a cMRI and pacing system related Adverse Device Effect (ADE)	1 and 3 months after cardiac MRI
Secondary	Pacemaker performance under/after MRI (short and midterm) - Pacing capture threshold (PCT) rise (atrial and ventricular)	The proportion of patients with an atrial or ventricular MRI induced pacing capture threshold rise larger than or equal to 100% voltage safety margin of the measured Pre-MRI pacing threshold at post-MRI interrogation, at 1-month and at 3 month follow- up; The proportion of patients with an atrial or ventricular MRI induced pacing threshold rise larger than or equal to 1.0 V @ 0.4 ms or 0.5 ms between pre-MRI and at post-MRI interrogation, 1 month and at 3-month follow-up	1 and 3 Months after cardiac MRI
Secondary	Pacemaker performance under/after MRI (short and midterm): atrial or ventricular sensing amplitude	- P and R-wave sensing attenuation: o The proportion of patients with an atrial or ventricular amplitude decrease that exceed 50% between Pre-MRI evaluation and at post-MRI interrogation, at 1-month and at 3-month follow-up	between Pre-MRI evaluation and at post-MRI interrogation at 1-month and at 3-month follow-up after cMRI
Secondary	- Long term pacing capture threshold rise (atrial and ventricular)	The proportion of patients with an atrial or ventricular MRI induced pacing capture threshold rise larger than or equal to 100% voltage safety margin of the measured Pre-MRI pacing threshold between Pre-MRI interrogation and at 2 years follow- up; The proportion of patients with an atrial or ventricular MRI induced pacing capture threshold rise larger than or equal to 1.0 V @ 0.4 ms or 0.5 ms between Pre-MRI interrogation and at 2 years follow- up	Pre-MRI interrogation and at 2 years follow- up
Secondary	- Long term P and R-wave sensing attenuation	The proportion of patients with an atrial or ventricular amplitude decrease that exceed 50% between Pre-MRI interrogation and 2 years follow-up	between Pre-MRI interrogation and 2 years follow-up
Secondary	MRI procedures during long term-follow up	Clinical incidence of MRI procedures during long term-follow up, device performance after repetitive MRI procedures	during a minimum of 2 years follow-up
Secondary	periprocedural cardiac troponin	Cardiac high sensitive Troponin pre- and post-MRI as marker of thermal injury	pre- and within 3 to 24 hours post-MRI